SCHEMBL14908010

SCHEMBL14908010

CN1C[C@H](c2ccccc2F)[C@@H](N)C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 5/20 0.59
KDM1B Q8NB78 1/20 0.59
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
HTR2C P28335 2/20 0.44
HTR2B P41595 2/20 0.44
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38
CYP3A4 P08684 1/20 0.38
MAPK1 P28482 1/20 0.37
RCOR1 Q9UKL0 1/20 0.37
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
SLC6A3 Q01959 2/20 0.37
DPP4 P27487 1/20 0.37
CHRM2 P08172 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
DRD2 P14416 1/20 0.37
GABRA1 P14867 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16110654 1.00 KDM1A (0.59) KDM1AKDM1BMEN1KMT2AHTR2C
SCHEMBL15064669 0.81 HTR2C (0.45) KDM1AMEN1KMT2AHTR2CHTR2B
SCHEMBL16110708 0.81 HTR2C (0.45) KDM1AMEN1KMT2AHTR2CHTR2B
SCHEMBL807474 0.81 HTR2C (0.45) KDM1AMEN1KMT2AHTR2CHTR2B
SCHEMBL18022528 0.81 MEN1 (0.51) KDM1AKDM1BMEN1KMT2AHTR2C
SCHEMBL21787709 0.81 MEN1 (0.51) KDM1AKDM1BMEN1KMT2AHTR2C
SCHEMBL16964887 0.79 HTR2C (0.48) KDM1AHTR2CHTR2BMAPK1HTR2A
SCHEMBL16109566 0.79 HTR2C (0.48) KDM1AHTR2CHTR2BMAPK1HTR2A
SCHEMBL14908034 0.79 HTR2C (0.48) KDM1AHTR2CHTR2BMAPK1HTR2A
SCHEMBL16964888 0.79 HTR2C (0.48) KDM1AHTR2CHTR2BMAPK1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2770987-B1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME (US) 2018-04-04 EP disclosed
US-9023865-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2015-05-05 US disclosed
US-9023865-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2015-05-05 US disclosed
US-20140296203-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME LLC 2014-10-02 US disclosed
US-20140296203-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME LLC 2014-10-02 US disclosed
WO-2013063214-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296203-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK10, MAP3K1 KDM1A 2668/4885KDM1B 3012/4885MEN1 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.